Evidence map›Paper›PMID 41150350›Full record

ArticleeLife2025

Nocebo effects are stronger and more persistent than placebo effects in healthy individuals.

Angelika Kunkel, Katharina Schmidt, Helena Hartmann, Torben Strietzel, Jens-Lennart Sperzel, Katja Wiech, Ulrike Bingel

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Angelika Kunkel *Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0001-8303-8693
Katharina Schmidt *Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0001-9397-5285
Helena HartmannDepartment of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0002-1331-6683
Torben StrietzelDepartment of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Jens-Lennart SperzelDepartment of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Katja Wiech *Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0002-5062-1046
Ulrike Bingel *Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0002-9528-3204

Funding

Deutsche Forschungsgemeinschaft 422744262
6 · The paper itself

Abstract

Placebo and nocebo effects illustrate the profound influence of cognitive-affective processes on symptom perception and treatment outcomes, with the potential to significantly alter responses to medical interventions. Despite their clinical relevance, the question of how placebo and nocebo effects differ in strength and duration remains largely unexplored. Using a within-subject design in 104 healthy individuals, we investigated and directly compared the magnitude and persistence of placebo and nocebo effects on experimental pain. Effects were assessed immediately after their induction through verbal instructions and conditioning and at a 1-week follow-up. The study was preregistered in the German Clinical Trials Register (registration number: DRKS00029228). Significant placebo and nocebo effects were detected on days 1 and 8, but nocebo effects were stronger on both test days. Sustained effects after 1 week were primarily predicted by individuals' experienced effects on day 1. Our findings underscore the enduring nature of placebo and nocebo effects in pain, with nocebo responses demonstrating consistently greater strength, which is consistent with an evolutionarily advantageous 'better-safe-than-sorry' strategy. These insights emphasise the significant impact of nocebo effects and stress the need to prioritise efforts to mitigate them in clinical practice.

Indexed as

Nocebo EffectPainPlacebo EffectAdolescentAdultFemaleHealthy VolunteersHumansMaleMiddle AgedPlacebosYoung AdultPlacebosconditioninghumanneurosciencenocebo hyperalgesiapain modulationplacebo hypoalgesiatreatment expectation

Identifiers

PMID41150350
PMCPMC12563545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.